When Angie Lachocki was diagnosed with pancreatic cancer, she was told she had less than two years to live.

More than two years later, Angie is still here, defying the odds.

Thanks to a groundbreaking clinical trial funded by Pancreatic Cancer Canada, Angie completed treatment in February 2024 after 12 rounds of chemotherapy and surgery. The trial, NeoPancONE, was the first in Canada to use chemo before and after surgery, tailored to patients with a specific biomarker.

Her story is one of innovation, strength, and survival. But it is also a stark reminder: stories like Angie’s are still the exception.

In our 2024 Impact Report, you will see how your support is improving lives but also why we must act with greater urgency.

As rates of pancreatic cancer rise, especially among younger people, Pancreatic Cancer Canada is meeting this urgent new reality head-on. In 2025 and beyond, we are unleashing a bold, disruptive transformation of our mission. We are widening our reach, deepening our impact, and accelerating breakthroughs to demand survival, not sympathy.

Our work is about more than hope; it is about mobilizing people to join us and to act. We are grateful to every donor, researcher, volunteer, and patient family helping turn action into life-saving change. By sharing stories like Angie’s, we are building a movement toward a future where survival is not the exception, it is the expectation.